Review Article

Women with Chronic Hepatitis C Virus Infection: Recommendations for Clinical Practice

Authors: Mary Jane Burton, MD, James B. Brock, MD, Stephen A. Geraci, MD


The natural history of hepatitis C virus infection differs between women and men. Women demonstrate a slow rate of disease progression until menopause. Older women are more likely to develop fibrosis and are less responsive than younger women to pegylated interferon and ribavirin. Women of childbearing age have higher rates of sustained virologic response, but current therapies are contraindicated during pregnancy. Vertical transmission of hepatitis C virus occurs, but data supporting recommendations for prevention of mother-to-infant transmission are limited.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus in the United States, 1999 through 2002. Ann Intern Med. 2006; 144: 705–714.
2. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med. 2000; 132: 296–305.
3. Alter MJ, Kruszon-Moran D, Nainan OV. The prevalence of hepatitis C virus infection in the United States, 1989–1994. N Engl J Med. 1999; 341: 556–562.
4. Armstrong GL. Injection drug users in the United States, 1979–2002, an aging population. Arch Intern Med. 2007; 167: 166–173.
5. Oh DJ, Park YM, Seo YI, et al. Prevalence of HCV infections and distributions of HCV genotypes among Korean blood donors. Ann Lab Med. 2012; 32: 210–215.
6. Vescio MF, Longo B, Babudieri S, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008; 62: 305–313.
7. Viitanen P, Vartiainen H, Aarnio J, et al. Hepatitis A, B,C and HIV infections among Finnish female prisoners—young females a risk group. J Infect. 2011; 62: 59–66.
8. Thorpe LE, Ouellet LJ, Levy JR, et al. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J Infect Dis. 2000; 182: 1588–1594.
9. Evans J, Hahn J, Page-Shafer K, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO study). J Urban Health. 2003; 80: 137–146.
10. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002; 155: 645–653.
11. Bennett GA, Velleman RD, Barter G, Bradbury C. Gender differences in sharing injecting equipment by drug users in England. AIDS Care. 2000; 12: 77–87.
12. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006; 13: 34–41.
13. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461: 798–801.
14. van der Berg CHBS, Grady BPX, Schinkel J, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One. 2011; 6: e27555
15. Rao HY, Sun DG, Jiang D, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012; 19: 173–181.
16. Kenny-Walsh E. Clinical outcomes of hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999; 340: 1228–1233.
17. Levine RA, Schuyler OS, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin. Gastroenterol Hepatol. 2006; 2006: 1271–1277.
18. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006; 43: 1303–1310.
19. Sarbah S, Gramlich T, Younoszai A, et al. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2004; 49: 850–853.
20. Codes L, Aselah T, Cazals-Hatem D, et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of menopause and steatosis and the potential benefit of hormone replacement therapy. Gut. 2007; 56: 390–395.
21. Xu J-W, Gong J, Chang XM, et al. Effects of estradiol on liver estrogen receptor-α and its mRNA expression in hepatic fibrosis in rates. World J Gastroenterol. 2004; 15: 250–254.
22. Xu JW, Gong J, Chang XM, et al. Estrogen reduces CCL4- induced liver fibrosis in rats. World J Gastroenterol. 2002; 8: 883–887.
23. Liu QH, Li DG, Huang X, et al. Suppressive effects of 17beta-estradiol on hepatic fibrosis in CCl4-induced rat model. World J Gastroenterol. 2004; 10: 1315–1320.
24. Hayashida K, Shoji I, Deng L, et al. 17β-estradiol inhibits the production of infectious particles of hepatitis C virus. Microbiol Immunol. 2010; 54: 684–690.
25. Martino VD, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology. 2004; 40: 1426–1433.
26. Poynard T, Mathurin P, Chin-Lung L, et al. E. A comparison of fibrosis progression in chronic liver disease. J Hepatol. 2003; 38: 257–265.
27. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999; 44: 874–880.
28. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49: 1335–1374.
29. Hezode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C and specific influence on steatosis: a prospective study. Aliment Pharmacol Ther. 2003; 17: 1031–1037.
30. Hu K-Q, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004; 40: 147–154.
31. Ortiz V, Berenguer M, Rayon JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002; 97: 2408–2414.
32. Hu SX, Kyulo NL, Xia VW, et al. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J Clin Gastroenterol. 2009; 43: 758–764.
33. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002; 51: 89–94.
34. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361: 580–593.
35. Fried MW, Shiffman M, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975–982.
36. Hayashi J, Kishihara Y, Ueno K, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med. 1998; 158: 177–181.
37. Sezaki H, Suzuki F, Kawamura Y, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009; 54: 1317–1324.
38. Villa E, Karampatou A, Cammà C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology. 2011; 140: 818–829.
39. Vertex Pharmaceuticals Antiviral Drugs Advisory Committee. Telaprevir 375-mg film-coated tablet for the treatment of genotype 1 chronic hepatitis C. FDA Briefing Document.…/UCM252562.pdf. Published April 28, 2011. Accessed November 13, 2012.
40. Merck & Co Antiviral Drugs Advisory Committee. Boceprevir capsules (NDA 202-258). FDA Briefing Document.…/UCM252343.pdf. Published March 29, 2011. Accessed November 13, 2012.
41. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for the retreatment of HCV infection. N Engl J Med. 2011; 364: 2417–2428.
42. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1207–1217.
43. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405–2416.
44. Latt NC, Spencer JD, Beeby PJ, et al. Hepatitis C in injecting drug-using women during and after pregnancy. J Gastroenterol Hepatol. 2000; 15: 175–181.
45. Reddick KLB, Jhaveri R, Gandhi M, et al. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat. 2011; 18: e394–e398.
46. Pergam SA, Wang CC, Gardella CM, et al. Pregnancy complications associated with hepatitis C: data from a 2003–2005 Washington state birth cohort. Am J Obstet Gynecol. 2008; 199: e1–e9.
47. Gervais A, Bacq Y, Bernuau J, et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol. 2000; 32: 293–299.
48. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med. 1994; 330: 744–750.
49. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. BMJ. 1998; 317: 437–441.
50. Mast EE, Hwang L-Y, Seto DSY, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005; 192: 1880–1889.
51. Dal Molin G, D’Agaro P, Ansaldi F, et al. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. J Med Virol. 2002; 67: 137–142.
52. Airoldi J, Berghella V. Hepatitis C and pregnancy. Obstet Gynecol Surv. 2006; 61: 666–672.
53. Murakami J, Nagata I, Iitsuka T, et al. Risk factors for mother-to-child transmission of hepatitis C virus: maternal high viral load and fetal exposure in the birth canal. Hepatol Res. 2012; 648–657.
54. Ogasawara S, Kage M, Kosai K-I, et al. Hepatitis C virus rNA in saliva and breastmilk of hepatitis C carrier mothers. Lancet. 1993; 341: 561
55. Lin H-H, Kao J-H, Hsu H-Y, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr. 1995; 126: 589–591.
56. American Academy of Pediatrics Committee on Infectious Diseases. Hepatitis C virus infection. Pediatrics. 1998; 101: 481–485.
57. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb Mortal Wkly Rep. 2010; 59:(No. RR-12): 87
58. Copegus [package insert]. Nutley, NJ: Roche Laboratories; 2011; .
59. Loustaud-Ratti V, Rousseau A, Marquet P, et al. Ribavirin in chronic hepatitis C: past and future. Expert Rev Anti Infect Ther. 2009; 7: 249–253.
60. Yazdani Brojeni P, Matok I, Garcia Bournissen F, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012; 33: 265–268.
61. Ozaslan E, Yilmaz R, Simsek H, et al. Interferon therapy for acute hepatitis C during pregnancy. Ann Pharmacother. 2002; 36: 1715–1718.
62. Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals; 2011; .
63. Victrelis [package insert]. Whitehouse Station, NJ: Merck & Co; 2011; .
64. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433–1444.